@article{14a63eeebb9b412da187f7834fb6ea10,
title = "Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer",
author = "{COVI3 study investigators} and Hagai Ligumsky and Herut Dor and Tal Etan and Inbal Golomb and Alla Nikolaevski-Berlin and Inbal Greenberg and Tamar Halperin and Yoel Angel and Oryan Henig and Avishay Spitzer and Marina Slobodkin and Ido Wolf",
note = "Funding Information: YA declares receiving research grants from Pfizer, outside the scope of this work. AS is partially supported by the Israeli Council for Higher Education via the Weizmann Data Science Research Center, and by a research grant from the Estate of Tully and Michele Plesser. IW reports speaker fees and fees for consultancy from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Beyond Air, AstraZeneca, and Novartis; contracts or research funding from Roche, Novatis, Beyond Air, and Merck Sharp & Dohme; participation on a data safety monitoring board or advisory board of Merck Sharp & Dohme and AstraZeneca; participation in committee of Israeli Cancer Association; and stock options in Breath of life. All other authors declare no competing interests. COVI3 study investigators are listed at the appendix (p 4) . ",
year = "2022",
month = feb,
doi = "10.1016/S1470-2045(21)00715-4",
language = "אנגלית",
volume = "23",
pages = "193--195",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier Ltd.",
number = "2",
}
